U.S. Markets open in 7 hrs 5 mins

New Strong Sell Stocks for April 16th

Zacks Equity Research
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q1 results on May 6.

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

Exterran Corporation EXTN is a systems and process company that offers solutions in power, water, oil and gas markets. The Zacks Consensus Estimate for its current year earnings has been revised 92.1% downward over the last 30 days.

Champions Oncology, Inc. CSBR is a developer and marketer of technology solutions and products that are used to personalize the usage and development of oncology drugs. The Zacks Consensus Estimate for its current year earnings has been revised 8.3% downward over the last 30 days.

Cross Country Healthcare, Inc. CCRN is a provider of healthcare staffing, recruiting and workforce solutions. The Zacks Consensus Estimate for its current year earnings has been revised 25% downward over the last 30 days.

Alaska Air Group, Inc. ALK is a provider of passenger and cargo air transportation services. The Zacks Consensus Estimate for its current year earnings has been revised 3.9% downward over the last 30 days.

BioMarin Pharmaceutical Inc. BMRN is a biotechnology company. The Zacks Consensus Estimate for its current year earnings has been revised 8.8% downward over the last 30 days.

View the entire Zacks Rank #5 List.


Is your investment advisor fumbling your financial future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.” Click to get your free report.
 
Alaska Air Group, Inc. (ALK) : Free Stock Analysis Report
 
BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report
 
Champions Oncology, Inc. (CSBR) : Free Stock Analysis Report
 
Cross Country Healthcare, Inc. (CCRN) : Free Stock Analysis Report
 
Exterran Corporation (EXTN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research